antibodi
carri
multitud
prevent
therapeut
antivir
activ
either
neutral
viral
particl
via
antigen
bind
fragment
fab
domain
interact
innat
immun
receptor
crystalliz
fragmentgamma
receptor
via
crystalliz
fragment
fc
domain
divers
mechan
elimin
target
expos
vulner
antigen
includ
antibodydepend
cellular
cytotox
adcc
antibodydepend
complementmedi
lysi
adcml
antibodydepend
cellular
phagocytosi
adcp
adcc
mediat
effector
cell
natur
killer
nk
cell
neutrophil
monocyt
releas
cytotox
molecul
elimin
viral
infect
cell
human
respons
initi
fc
region
subtyp
bind
activ
receptor
effector
cell
follow
crosslink
result
intracellular
signal
via
immunoreceptor
tyrosinebas
activ
motif
releas
granzym
b
perforin
granul
granzym
b
caus
dna
fragment
apoptosi
target
cell
addit
signal
via
also
lead
secret
sever
cytokin
chemokin
includ
tnf
inhibit
viral
spread
adcp
carri
monocyt
macrophag
neutrophil
eosinophil
phagocyt
engag
either
complement
receptor
andor
includ
addit
clear
antibodyopson
target
phagocytosi
signal
via
also
lead
secret
antivir
cytokin
final
adcml
initi
interact
igg
fc
complement
protein
drive
direct
cytotox
well
immunoregulatori
function
involv
enhanc
phagocytosi
stimul
antigenpres
cell
antibodymedi
effector
function
implic
protect
control
mani
virus
includ
influenza
virus
ebola
viru
ebov
human
immunodefici
viru
context
infect
use
broadli
neutral
antibodi
bnab
well
studi
current
evalu
prevent
control
infect
hiv
envelop
env
specif
antibodi
exhibit
high
potenc
neutral
breadth
across
differ
clade
numer
studi
passiv
administr
bnab
nonhuman
primat
model
protect
chimer
simianhuman
immunodefici
shiv
challeng
control
viremia
interestingli
recent
studi
also
suggest
besid
neutral
activ
bnab
fcmediat
effector
respons
adcc
import
prevent
control
viral
replic
vivo
diminish
bind
bnab
introduc
leucinetoalanin
substitut
lala
fc
region
significantli
reduc
protect
either
highdos
multipl
low
dose
shiv
challeng
rhesu
macaqu
similarli
studi
use
bnab
glycin
arginin
leucin
arginin
substitut
fc
region
grlr
diminish
fcdepend
function
reduc
bnab
capac
block
viral
entri
clear
cell
human
mice
model
interestingli
recent
studi
found
bnab
neutral
alon
might
suffici
protect
shivinfect
cell
challeng
rhesu
macaqu
conclus
made
compar
lala
counterpart
also
deplet
nk
cell
effect
protect
despit
studi
still
numer
line
evid
suggest
import
fcmediat
effector
function
elimin
cell
studi
shown
adcc
activ
antibodi
posit
correl
slower
diseas
progress
infect
individu
harbor
higher
titer
adccinduc
antibodi
shown
lower
viral
titer
higher
cell
count
lastli
antibodi
adcc
activ
presenc
low
plasma
iga
envspecif
antibodi
correl
decreas
acquisit
partial
success
vaccin
trial
numer
factor
govern
magnitud
antibodymedi
effector
function
viral
infect
cell
major
depend
abil
immun
complex
format
effici
effector
cell
activ
demonstr
degre
antibodi
bind
antigen
correl
adcc
suscept
lack
excess
bind
disrupt
abil
immun
complex
engag
effector
function
howev
antigen
bind
per
se
alway
trigger
adcc
respons
proper
engag
cluster
requir
activ
effector
cell
sinc
affin
antibodi
major
includ
low
micromolar
rang
multival
antibodyantigen
immun
complex
exert
enough
avid
cluster
activ
similarli
stoichiometri
orient
antibodi
bound
antigen
dictat
access
fc
domain
engag
appear
play
import
role
polymorph
human
greater
fc
bind
affin
also
influenc
occurr
infect
diseas
progress
viral
infect
includ
overal
level
specif
isotyp
subclass
antibodi
characterist
dictat
balanc
fcmediat
protect
diseas
progress
despit
recent
surg
studi
fcmediat
effector
function
control
viral
infect
remain
understudi
paramet
includ
viral
glycoprotein
shed
redirect
humor
immun
respons
infect
uninfect
cell
glycoprotein
intern
modul
immun
complex
format
abil
differ
famili
antibodi
synerg
effector
cell
activ
well
antibodi
glycosyl
review
summar
mechan
focu
draw
parallel
virus
final
consequ
mechan
determin
efficaci
fcmediat
effector
respons
implic
vaccin
design
therapeut
discuss
locat
presenc
immun
complex
dictat
target
cell
subject
effector
respons
redirect
humor
immun
respons
possibl
viral
glycoprotein
either
shed
secret
act
antigen
decoy
antibodi
sink
glycoprotein
shed
secret
infect
cell
occur
either
spontan
dissoci
transcript
translat
edit
activ
sheddas
metalloproteinas
strategi
antigen
subvers
solubl
glycoprotein
divert
immunomodulatori
effect
product
infect
cell
describ
mani
envelop
virus
includ
respiratori
syncyti
viru
rsv
ebov
discuss
envelop
glycoprotein
env
trimer
deriv
proteolyt
cleavag
trimer
precursor
compos
exterior
transmembran
subunit
sinc
noncoval
interact
two
subunit
result
spontan
dissoci
known
shed
surfac
product
infect
cell
consequ
signific
level
solubl
found
circul
blood
tissu
hivinfect
individu
shed
interact
receptor
surfac
uninfect
bystand
cell
well
establish
interact
critic
exposur
highli
conserv
epitop
adccmedi
antibodi
importantli
adccmedi
antibodi
natur
present
sera
hivinfect
individu
evolv
protect
infect
cell
recogn
antibodi
thu
bind
shed
receptor
uninfect
cell
redirect
adcc
respons
away
product
infect
cell
bystand
cell
phenomenon
report
richard
et
al
result
elimin
uninfect
bystand
cell
preferenti
bind
nonneutr
adccmedi
antibodi
bystand
cell
confirm
bruel
et
al
vivo
use
human
mice
model
horwitz
et
al
vivo
effect
shed
bind
surfac
bystand
lymphocyt
suggest
serv
effect
target
contribut
decreas
cell
count
individu
moreov
vitro
adcc
assay
greatli
influenc
redirect
adcc
toward
uninfect
cell
rsv
two
major
glycoprotein
attach
g
fusion
f
glycoprotein
addit
fulllength
membran
bound
g
solubl
form
sg
express
releas
infect
cell
sg
produc
altern
translat
initi
sensit
rsv
g
peptidas
cleavag
studi
bukreyev
et
al
examin
role
sg
vivo
use
mous
model
observ
sg
protect
rsv
replic
occupi
neutral
antibodi
addit
divert
g
fspecif
antibodi
respons
sg
also
inhibit
fcmediat
immun
respons
macrophag
complement
similarli
ebov
glycoprotein
gp
gene
also
undergo
transcript
edit
encod
secret
dimer
gp
sgp
protein
addit
studi
observ
involv
tumor
necrosi
factor
enzym
tace
proteolyt
cleavag
shed
ebov
gp
infect
cell
surfac
ebov
sgp
also
implic
imped
immunemedi
clearanc
ebov
infect
despit
structur
differ
gp
sgp
gp
trimer
sgp
form
homodim
share
crossreact
epitop
includ
nonneutr
antibodi
sgp
compet
thu
sgp
could
divert
fcmediat
effector
function
away
infect
cell
interest
hypothesi
remain
formal
test
support
idea
studi
use
mice
model
shown
bcell
respons
bias
toward
epitop
share
sgp
gp
render
antibodi
respons
suscept
sgp
competit
altogeth
find
highlight
relev
measur
impact
solubl
form
env
fcmediat
effector
function
vitro
vivo
format
stabl
immun
complex
present
effector
cell
anoth
signific
factor
dictat
effici
fcmediat
immun
respons
differ
virus
paramet
modifi
mani
way
includ
viral
envelop
protein
intern
characterist
observ
virus
includ
cytoplasm
domain
mani
viral
envelop
contain
endocyt
motif
mainli
tyrosinebas
dileucinebas
motif
recogn
adaptor
complex
ap
concentr
protein
within
clathrinco
vesicl
advantag
glycoprotein
endocytosi
virus
vari
promot
replic
hide
immun
respons
exampl
endocytosi
env
virus
nipah
viru
herp
simplex
virus
implic
regul
cellcel
fusion
spread
infect
lentivir
env
glycoprotein
includ
long
cytoplasm
domain
involv
regul
env
traffick
contain
sever
traffick
signal
includ
membraneproxim
tyrosinebas
sort
motif
interact
dileucin
motif
interact
endocytosi
recycl
env
suggest
essenti
mechan
env
incorpor
within
viral
particl
furthermor
studi
von
bredow
et
al
introduc
mutat
endocyt
motif
show
increas
cellsurfac
express
env
correl
increas
adcc
respons
consequ
author
suggest
role
env
endocytosi
protect
infect
cell
adcc
minim
env
exposur
intern
envelop
glycoprotein
cell
surfac
avoid
humor
immun
respons
observ
virus
includ
equin
pseudorabi
viru
wherein
downregul
envelop
protect
infect
cell
adcml
addit
spontan
envelop
endocytosi
previou
report
demonstr
antibodi
bind
induc
intern
antibodyenv
immun
complex
mechan
intern
result
crosslink
glycoprotein
depend
endocyt
motif
discuss
acceler
envelop
intern
upon
antibodi
bind
infect
cellsurfac
observ
sever
virus
includ
herpesvirus
rsv
felin
coronaviru
studi
fceffector
function
reduc
upon
addit
specif
antibodi
could
induc
glycoprotein
intern
reduct
adcml
pseudorabi
virusinfect
monocyt
similarli
reduct
antibodyinduc
env
intern
use
dynamin
inhibitor
enhanc
suscept
cell
adcc
interestingli
group
observ
antibodybound
env
protein
intern
env
conform
specif
manner
found
bnab
preferenti
recogn
close
state
env
conform
trigger
rapid
env
intern
compar
nonneutr
antibodi
preferenti
bound
open
state
env
conform
overal
result
suggest
paramet
modul
env
intern
potenti
impact
fcmediat
effector
function
cancer
field
lead
way
combin
monoclon
antibodi
mab
target
two
nonoverlap
antigen
epitop
enhanc
innat
antitumor
effector
immun
respons
current
antivir
strategi
also
includ
incorpor
mab
either
target
highli
conserv
epitop
combin
two
mab
target
variou
epitop
exampl
antivir
combin
therapi
use
mab
cocktail
includ
rabi
viru
variant
regard
recent
therapeut
design
passiv
immun
util
combin
bnab
suppress
viral
rebound
phase
clinic
trial
carri
mendoza
et
al
use
two
bnab
target
differ
epitop
bind
site
base
loop
antiretrovir
treatment
interrupt
observ
suppress
viral
rebound
without
develop
resist
virus
thirti
week
interestingli
previou
studi
highlight
import
engag
protect
infect
control
viral
load
human
mice
model
also
acceler
clearanc
infect
cell
therefor
combin
bnab
aid
prevent
emerg
antibodyresist
viral
variant
could
possibl
also
aid
clearanc
infect
cell
antibodymedi
effector
function
studi
teas
rel
contribut
neutral
prevent
infect
versu
elimin
infect
cell
fcmediat
effector
function
bnab
warrant
addit
recent
report
anoth
aspect
antibodi
cooper
clear
cell
observ
fc
region
two
famili
antibodi
env
requir
optim
engag
mediat
robust
adcc
interestingli
natur
occur
dimer
form
potent
neutral
antibodi
contain
four
fab
two
fc
region
previous
shown
potent
mediat
adcc
monomer
counterpart
altogeth
studi
suggest
multipl
antibodi
opson
infect
cell
surfac
enhanc
cluster
crosslink
activ
effector
cell
might
benefici
output
host
similarli
recent
studi
et
al
show
interact
among
ab
target
differ
epitop
polyclon
respons
significantli
modul
extent
fc
receptor
activ
influenza
viru
herein
author
demonstr
coordin
neuraminidasebind
ab
hemagglutinin
stalkbind
ab
induc
adcc
addit
manner
similarli
combin
mab
target
nonoverlap
epitop
ebov
reduc
viral
load
provid
signific
protect
ebov
diseas
evd
mous
guinea
pig
nonhuman
primat
studi
subsequ
treatment
approv
evd
treatment
ebov
outbreak
includ
zmapp
mab
cocktail
zmapp
consist
two
neutral
antibodi
nonneutr
antibodi
strikingli
remov
cocktail
shown
decreas
protect
ebov
suggest
fcmediat
effector
function
necessari
final
studi
pal
et
al
use
combin
antibodi
chikungunya
viru
chikv
limit
viral
resist
provid
vivo
protect
chikv
infect
importantli
therapeut
activ
one
chikv
antibodi
shown
depend
interact
thu
evid
support
import
polyclon
humor
respons
antibodi
target
multipl
specif
viral
infect
previous
discuss
amino
acid
mutat
within
fc
portion
ab
impact
abil
engag
modif
includ
lala
grlr
mutat
decreas
bind
gasdali
mutat
increas
bind
moreov
mutat
fc
domain
includ
yte
ls
substitut
enhanc
interact
neonat
fc
receptor
consequ
increas
serum
halflif
antibodi
extend
therapeut
effect
interestingli
glycosyl
divers
nacetylglucosamin
mannos
core
posit
asparagin
domain
anoth
fc
domain
modif
regul
effici
interact
human
exist
possibl
igg
glycan
subtyp
combin
due
presenc
termin
galactos
fucos
nacetylglycosamin
glcnac
sialic
acid
glycan
shown
influenc
bind
effector
cell
consequ
alter
antibodi
function
presenc
fucos
decreas
affin
fc
domain
therebi
reduc
effici
adcc
similarli
sialyl
addit
sialic
acid
also
enhanc
antiinflammatori
activ
reduc
affin
igg
fc
furthermor
termin
galactos
shown
increas
adcc
cdc
adcp
context
recent
studi
report
signific
differ
overal
igg
glycosyl
profil
depend
diseas
statu
individu
elit
control
harbor
nonfucosyl
less
sialyl
glycoform
compar
chronic
progressor
addit
nonfucosyl
galactosyl
antibodi
shown
neg
correl
level
cellassoci
hiv
dna
rna
antiretrovir
therapi
art
suppress
individu
addit
studi
understand
impact
fcglycosyl
viral
infect
cell
warrant
sinc
nonhuman
primat
studi
use
nonfucosyl
show
enhanc
protect
shiv
challeng
compar
wild
type
furthermor
studi
li
et
al
show
sialyl
fc
igg
diminish
affin
vitro
impact
outcom
vivo
sialyl
shown
significantli
decreas
adcc
presenc
fucosyl
impact
alon
current
research
enhanc
therapeut
activ
igg
antibodymedi
effector
function
viral
infect
focus
fcglycosyl
engin
nglycan
igg
protein
custom
use
biolog
medium
adapt
glycoengin
nicotiana
benthamiana
antibodi
glycoengin
exploit
improv
efficaci
interact
cell
accomplish
use
glycoform
lack
core
fucos
plantspecif
xylos
enhanc
antibodydepend
cellmedi
viru
inhibit
along
significantli
enhanc
bind
similar
modif
carri
bnab
fucos
xylosefre
glycoform
significantli
higher
affin
form
stabl
complex
induc
significantli
higher
adcc
infect
cell
respect
term
viral
infect
glycoengin
mab
produc
plant
incorpor
zmapp
cocktail
improv
efficaci
ebov
moreov
nonfucosyl
nongalactosyl
glycovari
palivizumab
mab
rsv
show
improv
vivo
protect
capac
decreas
viral
titer
despit
compar
neutral
capac
final
antibodi
glycoform
produc
n
benthamiana
lack
xylos
fucos
also
develop
candid
treat
west
nile
viru
dengu
viru
chikv
infect
discuss
glycosyl
heterogen
fc
portion
antibodi
dramat
impact
fcmediat
effector
function
gener
antibodi
near
homogen
glycosyl
facilit
reproduc
among
studi
gener
new
therapeut
becom
increasingli
clear
sever
factor
contribut
efficaci
fcmediat
effector
respons
viral
infect
cell
conform
env
recogn
given
antibodi
rate
intern
affin
antibodi
differ
fc
receptor
polymorph
modul
stress
ligand
viru
presenc
solubl
form
env
exampl
expand
number
paramet
govern
effector
function
better
understand
paramet
requir
improv
antibodi
therapeut
vaccin
design
